Cidara Therapeutics Inc   (CDTX)
Other Ticker:  
Price: $0.7287 $0.01 1.307%
Day's High: $0.7499 Week Perf: 5.61 %
Day's Low: $ 0.70 30 Day Perf: 9.6 %
Volume (M): 426 52 Wk High: $ 2.10
Volume (M$): $ 311 52 Wk Avg: $1.00
Open: $0.70 52 Wk Low: $0.59

 Market Capitalization (Millions $) 66
 Shares Outstanding (Millions) 90
 Employees -
 Revenues (TTM) (Millions $) 20
 Net Income (TTM) (Millions $) -28
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0

Cidara Therapeutics Inc
Cidara Therapeutics Inc is a biotechnology company focused on developing and commercializing novel antifungal and immunotherapy technologies. The company's goal is to address unmet medical needs in the treatment of serious fungal infections and provide innovative solutions for patients with compromised immune systems. Cidara's proprietary technology platforms, CloudbreakTM and Immunotherapy Platforms, aim to improve patient outcomes and reduce the risks associated with existing antifungal therapies. The company is committed to advancing its pipeline of drug candidates and revolutionizing the field of infectious diseases.

   Company Address: 6310 Nancy Ridge Drive, San Diego, 92121 CA
   Company Phone Number: 752-6170   Stock Exchange / Ticker: NASDAQ CDTX
   CDTX is expected to report next financial results on March 22, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Financing Agreement

A Milestone for Cidara Therapeutics: European Approval of REZZAYO Spurs $11.14 Million Payment and Improves Company Position

Published Mon, Feb 12 2024 1:01 PM UTC

A Milestone Achievement: Cidara Therapeutics Receives $11.14 Million Payment and Improves Leverage Ratio
San Diego-based biotechnology company, Cidara Therapeutics, Inc., announced the receipt of an $11.14 million milestone payment from Mundipharma after the European approval of REZZAYO (rezafungin acetate), a groundbreaking antifungal medication. This once-weekly echin...

Clinical Study

Revolution in Fungal Infection Treatment: REZZAYO (rezafungin) Gains Ground with a Nod from European Union

Published Fri, Dec 22 2023 12:30 PM UTC

The health and wellness sector announces a breakthrough as the European Union (EU) gives the green light for REZZAYO (rezafungin acetate), a proactive solution in the fight against invasive candidiasis in adults. The approval comes from Cidara Therapeutics, Inc., a biotech entity at the forefront of medicinal technology, listed on Nasdaq under the ticker symbol CDTX. This mi...

Clinical Study

Cidara Therapeutics Unveils Game-Changing Strategies: Novel Drug Conjugates and Inhibitors Show Promise in Revolutionizing Cancer Treatment

Published Thu, Dec 7 2023 1:01 PM UTC

Cidara Therapeutics, a renowned biotechnology company, recently unveiled groundbreaking preclinical data on two of its novel drug candidates at the ESMO Immuno-Oncology Annual Congress. The presentations centered around their dual-acting drug-Fc conjugates and a first-in-class CD73/PD-1 inhibitor.
Studies on the dual-acting drug-Fc conjugates demonstrated highl...


REZZAYO Shatters Expectations: Heralding a New Era in Candidemia and Invasive Candidiasis Treatment

Published Tue, Dec 5 2023 2:00 PM UTC

In an exciting development for the medical community, Melinta Therapeutics and Cidara Therapeutics have proudly announced the publication of landmark research assessing the efficacy and safety of their innovative drug, REZZAYO (rezafungin for injection), for the treatment of candidemia and invasive candidiasis. The peer-reviewed article, Efficacy and safety of reza...

Product Service News

Cidara Therapeutics Shatters Barriers with Dual-Acting Drug-Fc Conjugates: Unveiling Revolutionary Cancer Treatment at ESMO Immuno-Oncology Annual Congress

Published Thu, Nov 30 2023 1:00 PM UTC

Cidara Therapeutics, a biotechnology company specializing in the development of innovative therapies for cancer treatment, is set to unveil groundbreaking preclinical data on their novel dual-acting drug-Fc conjugates at the ESMO Immuno-Oncology Annual Congress. This exciting development marks the first-ever presentation of preclinical data on dual CD73/PD-1 target...


Cidara Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com